



FORM PTO-1462 (Rev. 1-2001) (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/941,897

ATTY. DOCKET NO.: N0260.70067US01

FILING DATE: August 28, 2001

CONFIRMATION NO.: 7824

APPLICANT: James Halbrook, et al.

GROUP ART UNIT: 1624

EXAMINER: Kifle, Bruck

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
BK ↓	A1	3,904,631		Elslager et al.	09-09-1975
	A2	4,539,412		Archer	09-03-1985
	A3	4,558,043		Wenk et al.	12-10-1985
	A4	6,555,593	B1	Hoyle et al.	04-29-2003
	A5	2001/0027210	A1	Wilson	10-04-2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
BK ↓	B1	DE	31 41 970	A1	VSESOJUZNYJ NAUČNO- ISSLEDOVATEL'SKIJ INSTITUT LEKARSTVENNYCH RASTENIJ	05-05-1983	N
	B2	EP	0 471 516	A1	IMPERIAL CHEMICAL INDUSTRIES PLC	02-19-1992	Y
	B3	JP	11-199565		TOYAMA CHEM. CO. LTD	07-27-1999	Abstract only
	B4	WO	02/20500	A2	ICOS CORPORATION	03-14-2002	Y
	B5	WO	01/17985	A1	INDENA S.P.A.	03-15-2001	Y
	B6	WO	96/16632	A1	LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER	06-06-1996	Abstract only
	B7	WO	92/16517	A1	XENOVA LIMITED	10-01-1992	Y
	B8	WO	90/14008	A1	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	11-29-1990	Y
	B9	WO	96/22077	A1	HENKEL KOMMANDITGESELLSCHAFT AUF	07-25-1996	Abstract only
	B10	WO	99/39247	A1	FIRST CHEMICAL CORPORATION	08-05-1999	Y

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
BK ↓	C1	ABADI, A.H., et al., "Synthesis, Antitumor and Antitubercular Evaluation of Certain New Xanthenone and Acridinone Analogs," <i>Arzneim.-Forsch./Drug Res.</i> 49 (1), Nr. 3, pp. 259-266 (1999)		
	C2	AGASIMUNDIN, Y.S., et al., "Furano compounds. XX. Synthesis of angular and linear furoxanthones," <i>Journal fuer Praktische Chemie</i> (Leipzig) (1972), 314(3-4), pp. 507-514	Abstract	
	C3	CROISY-DELCEY, M., et al., "Aza Analogues of Lucanthone: Synthesis and Antitumor and Bactericidal Properties," <i>J. Med. Chem.</i> (1983), 26, pp. 1329-1333		
	C4	FONTENEAU, N., et al., "Synthesis of quinone and xanthone analogs of rhein," <i>Tetrahedron</i> 57 (2001) pp. 9131-9135		
	C5	FUJIOKA, H., et al., "Activities of New Acridone Alkaloid Derivatives against Plasmodium yoelii		

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/941,897		ATTY. DOCKET NO.: N0260.70067US01	
MAR 29 2006		FILING DATE: August 28, 2001		CONFIRMATION NO.: 7824	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: James Halbrook, et al.			
		GROUP ART UNIT: 1624		EXAMINER: Kifle, Bruck	
Sheet	2	of	2		

OTHER ART — NON PATENT LITERATURE DOCUMENTS (continued)

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
BK		in vitro," <i>Arzneim.-Forsch./Drug Res.</i> 40 (II), Nr. 9 (1990), pp. 1026-1029	
	C6	GHOSH, C.K., et al., "Benzopyrans. Part 30. Synthesis of Substituted Xanthenes from 3-Acyl-2-methyl-1-benzopyran-4-ones," <i>Tetrahedron</i> Vol. 49, No. 19, pp. 4127-4134, 1993	
	C7	GOUD, A.N., et al., "Furan compounds. XVI," <i>Monatsh. Chem.</i> (1969), 100(1), pp. 38-41	Abstract
	C8	HARFENIST, M., et al., "Selective Inhibitors of Monoamine Oxidase. 3. Structure-Activity Relationship of Tricyclics Bearing Imidazoline, Oxadiazole, or Tetrazole Groups," <i>J. Med. Chem.</i> 1996, 39, pp. 1857-1863	
	C9	KLOPMAN, G., et al., "An artificial intelligence approach to the study of the structural moieties relevant to drug-receptor interactions in aldose reductase inhibitors," <i>Molecular Pharmacology</i> (1988), 34(6), pp. 852-862	Abstract
	C10	MARI, S., et al., "Flavone and xanthone derivatives related to fluoroquinolones," <i>Il Farmaco</i> 54 (1999) pp. 411-415	
	C11	TABARRINI, O., et al., "Design and Synthesis of Modified Quinolones as Antitumoral Acridones," <i>J. Med. Chem.</i> , 1999, Vol. 42, No. 12, pp. 2136-2144	
	C12	XUAN, T., et al., "Two new O- and C-glycosylxanthenes from the <i>Gentiana tizuensis</i> Franch," <i>Gaodeng Xuexiao Huaxue Xuebao</i> (2001), 22(10, Suppl.), pp. 148-150	Abstract

EXAMINER:	DATE CONSIDERED:
/Bruck Rifle/ (05/16/2006)	05/16/2006

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]